IDT Australia announces board shake-up
CMO IDT Australia (ASX:IDT) has announced a board reshuffle to support a planned expansion drive.
The company revealed that Alan Blackman and Robert Burnet - both of whom have been serving on the board for 27 years - will step down as directors at the end of June.
Reo Shigeno, CEO of Japanese clinical trial site management company I’rom Holdings’ Australian subsidiary, will join the board as a non-executive director. I’rom Holdings this month acquired an 18.8% stake in IDT Australia for $2 million in shares.
Also joining the board will be Australian biotechnology veteran Graeme Kaufman. A long-time former CSL executive, Kaufman is currently chairman of Bionomics (ASX:BNO) and a director at Cellmid (ASX:CMD).
IDT chairman and founder Dr Graeme Blackman will meanwhile step aside from the role during calendar Q3. A replacement will be selected in the interim.
The board shake-up comes one month after IDT appointed Dr Paul MacLeman as its new CEO. Prior to joining IDT Australia, MacLeman was most recently CEO of Genetic Technologies (ASX:GTG).
IDT Australia shares were trading unchanged at $0.25 as of around 1 pm on Thursday.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
